Skandinaviska Enskilda Banken AB publ Acquires 9,948 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Skandinaviska Enskilda Banken AB publ raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.2% in the 4th quarter, Holdings Channel reports. The firm owned 169,697 shares of the company’s stock after acquiring an additional 9,948 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Medpace were worth $56,546,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Proficio Capital Partners LLC increased its stake in Medpace by 34,497.4% in the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock worth $80,575,000 after buying an additional 241,827 shares during the period. Raymond James Financial Inc. acquired a new stake in Medpace in the fourth quarter valued at approximately $78,144,000. Iron Triangle Partners LP purchased a new stake in shares of Medpace during the third quarter worth about $64,371,000. GW&K Investment Management LLC increased its stake in Medpace by 93.9% during the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock valued at $91,516,000 after purchasing an additional 133,379 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after acquiring an additional 109,886 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Trading Down 0.3 %

Shares of NASDAQ:MEDP opened at $324.91 on Thursday. The firm has a 50 day simple moving average of $340.91 and a 200-day simple moving average of $342.00. The company has a market capitalization of $9.90 billion, a PE ratio of 25.73, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.